FDA hits pause on natural food dye approvals, leaving brands in limbo

The FDA has reportedly hit pause on approving two natural food dyes — a spirulina-derived blue and a butterfly pea flower extract — that were expected to help replace synthetic colors like Red 40 and Yellow 5 in the U.S. food supply, as reported by Food Dive. The delay came after safety reviewers raised toxicological objections during the review process, throwing a wrench into what many food manufacturers assumed would be a straightforward regulatory path. But the real story here isn't bureaucratic sluggishness — it's the collision between surging consumer demand for clean-label products and a regulatory apparatus that was never designed to move at the speed of market trends. That collision is now creating a no-man's-land for some of the biggest names in food, and the fallout could reshape the clean-label timeline for years.

The conventional thinking has been that natural dyes are inherently safer than their synthetic counterparts — a belief that has driven billions of dollars in reformulation investment across the CPG landscape. But the FDA's safety reviewers raised concerns about potential allergenicity and insufficient toxicological data on these specific colorant compounds at the concentrations proposed for widespread use. That's a reminder that "natural" on a label doesn't automatically mean a substance has cleared every toxicological hurdle. Arsenic is natural. So is ricin. The assumption that botanical origin equals safety is a consumer myth that the industry has been happy to ride — until the regulatory reality catches up.

The timing is especially brutal. There has been political pressure to move away from artificial food colorings, and major CPG brands have already been reformulating products in anticipation of a regulatory shift toward natural alternatives. Companies like General Mills, which moved to remove artificial colors from its cereals including Trix and Lucky Charms, and Mars, which committed to transitioning its candy lines, have spent years and significant R&D budgets building reformulation pipelines around the expected availability of these approved natural alternatives. Kraft Heinz reformulated its iconic macaroni and cheese away from Yellow 5 and Yellow 6 years ago, relying on paprika, annatto, and turmeric — but brands seeking blue and violet hues have far fewer approved options, which is exactly where spirulina and butterfly pea flower were supposed to fill the gap. With these approvals now in limbo, companies that jumped ahead of the curve find themselves stuck between ingredients the FDA wants to phase out and replacements it hasn't fully cleared.

This is what happens when consumer demand outpaces regulatory infrastructure. The broader push to clean up the food supply has gained momentum over the past several years, but the agency's own track record on ingredient safety reviews has drawn serious scrutiny. Reports indicate that the FDA did not perform safety checks on more than 100 food ingredients, raising questions about how the agency prioritizes its resources and whether its review processes are keeping pace with the industry's rapid reformulation efforts. The GRAS (Generally Recognized as Safe) loophole has allowed companies to self-certify many ingredients without FDA review, creating a system where market pressure — not scientific rigor — often determines what ends up in the food supply. Now, ironically, the same agency that has been criticized for being too permissive is being too slow on the very alternatives the market is demanding.

For the plant-based and clean-label food space, this delay matters acutely. Color is one of the most visible signals consumers use to judge whether a product looks appealing, and many plant-based brands — from Beyond Meat's packaging aesthetics to the vibrant smoothie bowls sold by companies like Daily Harvest and Koia — have leaned heavily on natural colorants as a selling point. If the FDA's safety review process slows the pipeline of approved natural alternatives, it could create real formulation headaches for brands trying to ditch synthetic dyes while still making food that looks good on a shelf. Startups in the alternative protein space, which already operate on razor-thin margins, may face the unappealing choice of either reverting to synthetic dyes (and losing their clean-label positioning) or accepting dull, less marketable product appearances.

The FDA hasn't provided a clear timeline for when the review might conclude, but the implications are already concrete. Brands with products in reformulation pipelines now face a choice: hold their current synthetic formulations and risk consumer backlash, switch to already-approved but limited natural alternatives like beet juice or turmeric that can't replicate every color profile, or reformulate around the delay entirely by redesigning products to avoid the colors they can't naturally achieve. None of those options are cheap, and none are fast. Industry analysts had projected that the U.S. natural food colorant market would surpass $1.5 billion by 2027, but that trajectory assumed a cooperative regulatory environment. What we're seeing instead is the clean-label movement hitting a wall it didn't anticipate — not consumer resistance, not cost, but the uncomfortable fact that the science of safety doesn't bend to the marketing calendar. Companies that built their brand promise around "no artificial anything" may have written a check that the FDA isn't ready to cash.